Piroxicam

Specifications

36322-90-4CAS Number

252-974-3EC Number

4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamideIUPAC Name

C15H13N3O4SChemical Formula

331.3 g/molMolecular Weight

piroxicam; 36322-90-4; Feldene; Piroxicamum; Pyroxycam; Roxicam; BAXO; Piroftal; CP-16171; Larapam; CP 16171; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; CHF 1251; DTXSID5021170; 13T4O6VMAM; NSC-666076; CHEBI:8249; CP-16,171; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; NSC666076; DTXCID401170; 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; CP16171; Flamatrol; Kentene; Feldene p; 4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1$l^(6),2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1$l^{6},2-benzothiazine-3-carboxamide; Piroflam 10; Piroflam 20; Feldene 20; Pirozip 10; Pirozip 20; RefChem:6147; M01AC01; M02AA07; S01BC06; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboximide-1,1-dioxide; 252-974-3; Brexidol; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; Artroxicam; C15H13N3O4S; NSC 666076; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; MFCD00057317; 1044566-76-8; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; MLS000069644; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 2H-1,2-Benzothiazine-3-carboxamide,4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; NCGC00015823-02; Bruxicam; Caliment; Flogobene; Geldene; Improntal; Piroflex; Reudene; Roxiden; Sasulen; SMR000035997; Solocalm; Erazon; Pirkam; Riacen; Zunden; Roxam; CAS-36322-90-4; Piroxicamum [INN-Latin]; (3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; Rosiden; Felden; Feldene Fast; Feldene Gel; (4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamid e; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide; Feldene (TN); Piroxicam (Feldene); CCRIS 3719; SR-01000000199; EINECS 252-974-3; AK1015; UNII-13T4O6VMAM; BRN 0627692; Flamatrol;; Improntal;; Cycladol;; Piroflam;; Larapam;; Pirozip;; Reudene;; Brexin;; Piroxicam CRS; Fasax;; Pirox;; Prestwick_573; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; Piroxicam (Standard); Piroxicam [USAN:USP:INN:BAN:JAN]; piroxicam:malonic acid; Spectrum_001115; Tocris-0960; Opera_ID_442; PIROXICAM [INN]; PIROXICAM [JAN]; Piroxicam: Form Alpha1; Piroxicam: Form Alpha2; PIROXICAM [MI]; PIROXICAM [USAN]; Prestwick0_000211; Prestwick1_000211; Prestwick2_000211; Prestwick3_000211; Spectrum2_001287; Spectrum3_000780; Spectrum4_000968; Spectrum5_001445; Lopac-P-5654; PIROXICAM [VANDF]; PIROXICAM ANHYDROUS; CHEMBL527; Epitope ID:613453; PIROXICAM [MART.]; P 5654; PIROXICAM [USP-RS]; PIROXICAM [WHO-DD]; BIDD:PXR0154; Lopac0_000900; Oprea1_714707; SCHEMBL13462; SCHEMBL21350; BSPBio_000221; BSPBio_001030; BSPBio_002460; KBioGR_000370; KBioGR_001315; KBioSS_000370; KBioSS_001595; MLS000038002; MLS001148207; MLS001304054; MLS004774122; DivK1c_000369; SPECTRUM1500491; SPBio_001293; SPBio_002142; Piroxicam (JP18/USP/INN); BPBio1_000245; GTPL7273; orb1310318; Piroxicam, >=98% (TLC); SCHEMBL3703617; PIROXICAM [ORANGE BOOK]; Piroxicam for system suitability; CHEMBL1518938; PIROXICAM [EP MONOGRAPH]; SCHEMBL29352427; SCHEMBL29396075; BCBcMAP01_000176; BDBM85245; HMS501C11; HY-B0253R; KBio1_000369; KBio2_000370; KBio2_001595; KBio2_002938; KBio2_004163; KBio2_005506; KBio2_006731; KBio3_000719; KBio3_000720; KBio3_001680; MSK7162; PIROXICAM [USP MONOGRAPH]; NINDS_000369; Piroxicam 1.0 mg/ml in Methanol; Bio1_000363; Bio1_000852; Bio1_001341; Bio2_000355; Bio2_000835; GLXC-26155; GLXC-26156; HMS1362D11; HMS1568L03; HMS1792D11; HMS1920H22; HMS1990D11; HMS2089B06; HMS2092A05; HMS2095L03; HMS2231G03; HMS3262D22; HMS3267I03; HMS3369B07; HMS3403D11; HMS3414H17; HMS3429L03; HMS3655C04; HMS3678H15; HMS3712L03; HMS3884C08; HMS5079F16; Pharmakon1600-01500491; HY-B0253; NSC_4856; Tox21_110231; Tox21_200151; Tox21_500900; BBL016493; CCG-36403; EBC-11158; EBC-26614; MSK7162-100A; NSC757284; Piroxicam for system suitability CRS; s1713; STK177288; AKOS000714958; AKOS025312555; AKOS026749939; MSK7162-1000A; Tox21_110231_1; DB00554; FP27085; KS-5322; LP00900; NSC-757284; SDCCGSBI-0050875.P005; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; IDI1_000369; IDI1_002110; NCGC00015823-01; NCGC00015823-03; NCGC00015823-04; NCGC00015823-05; NCGC00015823-06; NCGC00015823-07; NCGC00015823-08; NCGC00015823-09; NCGC00015823-10; NCGC00015823-11; NCGC00015823-12; NCGC00015823-13; NCGC00015823-14; NCGC00015823-15; NCGC00015823-17; NCGC00015823-18; NCGC00015823-20; NCGC00015823-29; NCGC00021244-03; NCGC00021244-05; NCGC00021244-06; NCGC00021244-07; NCGC00021244-08; NCGC00021244-09; NCGC00188982-01; NCGC00257705-01; NCGC00261585-01; (Z)-3-(hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide; AC-24190; NCI60_022912; ST069379; SBI-0050875.P004; CAS_36322-90-4; Piroxicam, meets USP testing specifications; EU-0100900; NS00015466; P1905; P3269; SW219862-1; EN300-70724; Piroxicam Solution in Acetonitrile, 100ug/mL; C01608; D00127; D70554; Piroxicam Solution in Acetonitrile, 1000ug/mL; AB00052074-21; AB00052074-22; AB00052074_23; AB00052074_24; F340495; Q408676; SR-01000000199-3; SR-01000000199-5; SR-01000000199-9; SR-01000000199-12; F0001-2399; Piroxicam, British Pharmacopoeia (BP) Reference Standard; Z1137167677; Piroxicam, European Pharmacopoeia (EP) Reference Standard; Piroxicam, United States Pharmacopeia (USP) Reference Standard; Piroxicam, Pharmaceutical Secondary Standard; Certified Reference Material; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1lambda6,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide; 4-Hydroxy-2-methyl-N-(pyridin-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide1,1-dioxide; N-(2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; (Z)-3-(Hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 3-(Hydroxy[(pyridin-2-yl)amino]methylidene)-2-methyl-3,4-dihydro-2h-1lambda(6),2-benzothiazine-1,1,4-trione; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione; 3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1lambda6,2-benzothiazine-1,1,4-trione; 4-Hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine -3-carboxamide-1,1-dioxide malonic acidSynonyms